Correlation between immune-related adverse events and prognosis in patients with various cancers treated with anti PD-1 antibody

Correlation between immune-related adverse events and prognosis in patients with various cancers treated with anti PD-1 antibody

Abstract Background Immune checkpoint inhibitors (ICIs) targeting programmed cell death protein 1 (PD-1) are used for the treatment of various cancer types. However, immune-related adverse events (irAEs) occur in patients treated with ICIs. Several small-scale studies have reported the onset of irAE...

Full description

Bibliographic Details
Main Authors: Hiroshi Matsuoka, Takahiro Hayashi, Karen Takigami, Kazuyoshi Imaizumi, Ryoichi Shiroki, Naoki Ohmiya, Kazumitsu Sugiura, Kenji Kawada, Akira Sawaki, Koutaro Maeda, Yousuke Ando, Ichiro Uyama
Format: Article
Language:English
Published: BMC 2020-07-01
Series:BMC Cancer
Subjects:
Immune-related adverse events
Programmed cell death-1
Nivolumab
Pembrolizumab
Online Access:http://link.springer.com/article/10.1186/s12885-020-07142-3

Internet

http://link.springer.com/article/10.1186/s12885-020-07142-3

Similar Items